Welcome to our dedicated page for IIN news (Ticker: IIN), a resource for investors and traders seeking the latest updates and insights on IIN stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IIN's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IIN's position in the market.
Intricon Corporation (NASDAQ: IIN) has appointed David Liebl as its new Vice President of R&D, effective immediately. With over 25 years of experience in engineering and product development, Liebl's previous roles include President of Biomerics and various executive positions at Heraeus Medical Components. The company aims to strengthen its talent pool to enhance its position as a Joint Development Manufacturer. CEO Scott Longval expressed excitement about Liebl's addition, highlighting the importance of advancing their capabilities in high-growth markets.
Intricon Corporation (NASDAQ: IIN) announced the release of its 2021 second quarter results on August 9, 2021, after market close. A conference call will follow at 4:00 p.m. CT/5:00 p.m. ET, accessible via phone or webcast. Intricon specializes in designing and manufacturing miniature medical devices, emphasizing collaboration throughout the development process. With facilities in the U.S., Asia, and Europe, the company is committed to advancing micro-medical technology for global clients and improving clinical outcomes.
Intricon Corporation (NASDAQ: IIN) reported strong Q1 2021 financial results with revenue of $31.8 million, an increase of $10.3 million from Q1 2020. The gross margin improved to 25.8%, up from 21.3% year-over-year. The company achieved a GAAP net income of $0.7 million or $0.07 per diluted share, reversing a net loss of $2.0 million in the prior period. Non-GAAP adjusted net income was $2.5 million or $0.26 per diluted share. The company anticipates full-year revenue growth of 16-20% despite ongoing pandemic impacts.
Intricon Corporation (NASDAQ: IIN) announced it will release its 2021 first quarter results on May 10, 2021, after market close. Following the announcement, a conference call with management is scheduled for 4:00 p.m. CT/5:00 p.m. ET on the same day. Investors can join the call by dialing (866) 795-7248 for domestic or (470) 495-9160 for international participants, using conference ID: 9769435. A live and archived webcast will also be available on the company’s website.
Intricon specializes in designing and manufacturing miniature medical devices and operates globally.
Intricon Corporation announced the appointment of Kathleen Pepski to its Board of Directors, effective March 19, 2021. Pepski brings over 30 years of finance and accounting experience, including leadership roles at Hawkins, Inc. and PNA Holdings. Her expertise in manufacturing, distribution, and mergers and acquisitions is expected to support Intricon's long-term growth strategy. CEO Scott Longval and Chairman Philip I. Smith expressed confidence in Pepski's ability to add value, particularly in innovation within the miniature medical device sector.
Intricon Corporation (NASDAQ: IIN) reported fourth quarter and full-year financial results for 2020. Fourth quarter revenue reached $30.3 million, up from $27.7 million year-over-year, while full-year revenue totaled $102.8 million, down from $113.5 million in 2019. Notably, other medical revenue surged 74.3% due to the acquisition of Emerald Medical Services, offsetting a 13.5% decline in diabetes revenue. The company posted a fourth quarter net income of $1.1 million or $0.12 per diluted share, improving from $0.08. However, 2020 ended with a net loss of $2.5 million.
Intricon Corporation (NASDAQ: IIN) announced its intent to release the 2020 fourth quarter and full year results on February 25, 2021, after market close. The management team will hold a conference call at 4:00 p.m. CT/5:00 p.m. ET on the same day, accessible via a designated call-in number. A live webcast will also be available on Intricon's website. As a Joint Development Manufacturer, Intricon focuses on enhancing micro-medical technology, partnering closely with customers throughout the development process to improve clinical outcomes.
Intricon Corporation (NASDAQ: IIN) appoints Ellen Scipta as its Chief Financial Officer (CFO), effective immediately. Scipta brings over 20 years of financial leadership, previously serving as Vice President of Finance at Bio-Techne. Intricon's CEO, Scott Longval, highlights Scipta’s engineering and financial expertise, which will enhance the company's growth and operational efficiency. She holds an MBA in Finance and Strategy and a B.S. in Aeronautical Engineering. Intricon focuses on advancing micro-medical technology with a commitment to customer engagement.
Intricon Corporation reported a solid performance for Q3 2020, achieving revenues of $27.4 million, a slight increase from $26.9 million year-over-year. The medical segment, bolstered by the acquisition of Emerald Medical Services, saw revenue rise to $20.6 million. However, diabetes revenue fell by 7.7%, while hearing health revenue dropped from $6.4 million to $5.5 million attributed to restructuring efforts. Gross margin improved to 26.3% from 25.2% and the company reported a net income of $0.6 million, or $0.07 per diluted share, compared to a loss last year.
IntriCon Corporation (NASDAQ: IIN) will present at the Virtual 2020 Stifel Healthcare Conference on November 18, 2020, at 10:40 a.m. Eastern Time. CEO Scott Longval will lead the presentation, highlighting the company's innovations in body-worn devices. The conference offers a platform for potential investors and interested parties to gain insights into IntriCon's advanced manufacturing capabilities and market positioning. A live and archived webcast will be accessible via the company’s website.
FAQ
What is the market cap of IIN (IIN)?
